scholarly journals Different metabolic responses induced by long-term interdisciplinary therapy in obese adolescents related to ACE I/D polymorphism

2017 ◽  
Vol 18 (2) ◽  
pp. 147032031770345 ◽  
Author(s):  
Sandro S Almeida ◽  
Flavia C Corgosinho ◽  
Carlos EN Amorim ◽  
Marcos F Gregnani ◽  
Raquel MS Campos ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Low Density Lipoprotein ◽  
Insulin Response ◽  
Density Lipoprotein ◽  
Fat Free Mass ◽  
Interdisciplinary Therapy ◽  
Obese Adolescents ◽  
Cholesterol Levels ◽  
The Metabolic Syndrome

Introduction: The main purpose of the present study was to investigate whether I/D polymorphism of the ACE gene might affect metabolic changes related to the metabolic syndrome through a long-term interdisciplinary therapy in obese adolescents. Methods: In total, 125 obese adolescents who entered the interdisciplinary obesity programme were assigned to the following two subgroups: metabolic syndrome or non-metabolic syndrome. They were evaluated at baseline and after 1 year. Genomic DNA was extracted from circulating leukocytes. Results: Subjects with the II genotype in the non-metabolic syndrome group were only to increase their fat-free mass after therapy. Regarding lipid profile, subjects with ID and DD genotypes from both groups reduced their low-density lipoprotein cholesterol levels significantly. The metabolic parameters from the ID and DD genotypes of the non-metabolic syndrome group showed a significantly improved insulin response. Conclusion: In the present study, we showed that the ACE polymorphism was able to influence the fat-free mass in the I-carry allele in the non-metabolic syndrome group positively. In addition, the I-carry allele was able to improve the insulin resistance of the metabolic syndrome group significantly. These results suggest that the ACE I/D genotypes can influence, in different ways, the specific parameters of metabolism among obese adolescents submitted for long-term interdisciplinary therapy.

Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades

2013 ◽  
Vol 24 (3) ◽  
pp. 437-441 ◽  
Author(s):  
Avishay Elis ◽  
Rong Zhou ◽  
Evan A. Stein
Keyword(s):  
Children And Adolescents ◽  
Familial Hypercholesterolaemia ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels ◽  
Heterozygous Familial Hypercholesterolaemia

AbstractBackground:This study evaluated the effectiveness of long-term intensive lipid-lowering therapy in children and adolescents with familial hypercholesterolaemia.Methods:The charts of 89 children and adolescents with heterozygous familial hypercholesterolaemia among ∼1000 patients treated from 1974 to 2008 were reviewed. Familial hypercholesterolaemia was defined as low-density lipoprotein cholesterol level >90th percentile in individuals with a history of familial hypercholesterolaemia.Results:Of the 89 patients, 51% were male; the mean age at diagnosis was 8 ± 4 years, and the mean follow-up was 13 ± 8 years. Baseline and most recent low-density lipoprotein cholesterol levels (mg/dl) under treatment were 250 ± 50 and 142 ± 49, respectively, reduced 43% from baseline (p < 0.0001). At the most recent visit, 39 patients received statin monotherapy, mainly atorvastatin or rosuvastatin, and 50 (56%) patients received combination therapy, mainly vytorin or rosuvastain/ezetimibe, 15 patients were >30 years of age, and none developed symptomatic cardiovascular disease or needed revascularisation.Conclusions:Long-term statin-based therapy can reduce low-density lipoprotein cholesterol levels in most children and adolescents with heterozygous familial hypercholesterolaemia and decrease cardiovascular risk significantly.

scholarly journals Study on health risk factors as a basis to implement programs that promote a nutritional culture in students of the la Sabana University

2021 ◽  
pp. 89-94
Keyword(s):  
Physical Activity ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Chemistry ◽  
Monitoring And Control ◽  
The Metabolic Syndrome

Background. Nowadays the importance of lifestyles in the prevention of type 2 diabetes and the metabolic syndrome has been largely accertained. Objective. The purpose of our work is to implement programs that promote a nutritional culture in adolescents and young adults of the La Sabana University. Methods. The methodology entailed, after the corresponding informed consent, taking measures of the triceps and supraescapular skinfolds, waist circumference, body mass index (BMI), lean mass, and fat mass. Fasting blood samples were also taken to quantify cholesterol, triglycerides, high density lipoprotein (HDL) and low density lipoprotein (LDL). Results. The results obtained show that of the 165 students, 10.3% were underweight, 13.93% were overweight and 0.6% were obese. With regards to gender, 4.8% of the men and 9% of the women were overweight, 3% of the men and 7.2% of the women were underweight, and 0.6% of the women were obese. The blood chemistry showed that 30% had hypercholesterolemia, 18% hypertriglyceridemia, 17% reported low HDL levels and 67% reported high LDL levels. Of all the cases studied, 40% are at risk of a metabolic syndrome. 60% claimed not to practice any physical activity - especially women who reported 44.70%. Conclusions. These findings have allowed us at the institution to implement a culture of healthy habits. The have also allowed us to identify students with risk factors for type 2 diabetes and metabolic syndrome. This is why the cardiometabolic monitoring and control based on healthy eating and physical activity are important.

Autoantibodies against modified apolipoprotein B-100 in relation to low-density lipoprotein size and the metabolic syndrome in otherwise healthy men

Metabolism ◽  
2008 ◽  
Vol 57 (3) ◽  
pp. 362-366 ◽  
Author(s):  
Per Sjögren ◽  
Gunilla N. Fredrikson ◽  
Magdalena Rosell ◽  
Ulf de Faire ◽  
Anders Hamsten ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Healthy Men ◽  
The Metabolic Syndrome ◽  
Lipoprotein Size

scholarly journals On the Severity of Carpal Tunnel Syndrome: Metabolic Syndrome or Obesity

2020 ◽  
Vol 8 (A) ◽  
pp. 606-610
Author(s):  
Angelo Vasiliadis ◽  
George Charitoudis ◽  
Theofanis Kantas ◽  
George Giovanidis ◽  
George Biniaris
Keyword(s):  
Metabolic Syndrome ◽  
Waist Circumference ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels ◽  
Tunnel Syndrome ◽  
The Mean ◽  
The Relationship

AIM: This study aimed to determine the relationship between CTS, metabolic syndrome and obesity and to compare the severity of CTS between patients with or without metabolic syndrome (MS) and patients with or without obesity. METHODS: In this prospective study, patients with clinical and electrophysiological confirmed diagnosis of CTS were included. The waist circumference, blood pressure, fasting blood glucose, fasting triglycerides and high/low density lipoprotein cholesterol levels were recorded. Patients were categorized having metabolic syndrome according to Adult Treatment Panel III definition, while body mass index was used to identify obesity. RESULTS: A total of 65 patients with a mean age of 58.91 ± 12.49 years were included. MS was found in 39 (60%) patients and obesity in 27 (41.5%) patients. The CTS was described as mild, moderate and severe in 8, 12 and 19 hands of those with MS and in 2, 6, and 18 of those without MS respectively (p = 0.207). There were no statistically significant results observed between BMI and the severity of CTS (p > 0.05). The mean waist circumference was 94.75 ± 7.36, 98.78 ± 9.64, 106.42 ± 10.78, 86.41 ± 6.77 for patients with MS+_O–, MS–O+_, MS+_O+_ _and MS–O– _respectively (p < 0.002). CONCLUSION: CTS appears to be more severe in patients with MS than in patients with obesity. Central obesity is one of the well-known risk factors for CTS, but components of MS may have a greater effect on the severity of CTS.

scholarly journals Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity

2020 ◽  
Vol 105 (8) ◽  
pp. 2719-2731
Author(s):  
Charlotte D C C van der Heijden ◽  
Rob ter Horst ◽  
Inge C L van den Munckhof ◽  
Kiki Schraa ◽  
Jacqueline de Graaf ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Systemic Inflammation ◽  
Carotid Atherosclerosis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Metabolic Disturbances ◽  
Cross Sectional ◽  
Metabolic Dysregulation ◽  
Markers Of Inflammation ◽  
The Metabolic Syndrome

Abstract Context Not all obese individuals develop cardiovascular disease (CVD). Hyperaldosteronism is suggested to cause inflammation and metabolic dysregulation, and might contribute to CVD development in obese individuals. Objective We aimed to investigate the association of aldosterone concentrations with inflammation, metabolic disturbances, and atherosclerosis in overweight and obese individuals. Additionally, we measured renin concentrations to investigate whether the observed effects reflected general activation of the renin-angiotensin-aldosterone system (RAAS). Design A cross-sectional cohort study (300-OB study) was conducted. Various inflammatory parameters, traits of the metabolic syndrome, lipidome and metabolome parameters, fat distribution, and carotid atherosclerosis were associated with plasma aldosterone and renin levels. Setting The setting of this study was the Radboudumc (i.o. Radboudumc), the Netherlands. Patients A total of 302 individuals with a body mass index greater than or equal to 27 kg/m2 participated. Main Outcome Measures and Results Aldosterone was associated with various markers of inflammation and metabolic dysregulation, which partly differed from the associations observed for renin. Although both were associated with inflammatory cell numbers, only renin was associated with classical markers of systemic inflammation. Both were associated with the metabolic syndrome and hepatic steatosis. Of the traits that constitute metabolic syndrome, aldosterone, but not renin, was associated with triglyceride concentrations. Accordingly, aldosterone was associated with large very low-density lipoprotein particles; metabolomics studies further associated aldosterone with urate concentrations and derivatives of the linoleic acid metabolism pathway. Neither aldosterone nor renin was associated with atherosclerotic plaque thickness. Conclusions Aldosterone is not an important driver of systemic inflammation in the obese, whereas aldosterone concentrations and metabolic dysregulation are strongly intertwined in these individuals. Although prospective studies are necessary to validate these results, the independent effects of aldosterone on carotid atherosclerosis appear modest.

Abstract 3733: Postprandial Free Fatty Acid Metabolism During Fenofibrate Treatment Predicts Postprandial Lipid And Lipoprotein Changes

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Robert S Rosenson
Keyword(s):  
Metabolic Syndrome ◽  
Test Meal ◽  
Low Density Lipoprotein ◽  
Area Under The Curve ◽  
Density Lipoprotein ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
The Metabolic Syndrome ◽  
Ldl Particles ◽  
Postprandial Triglycerides

Objective: To determine the effects of fenofibrate (160 mg/d) on fasting and postprandial non-esterified fatty acids (NEFA) and lipoproteins in subjects with hypertriglyceridemia and the metabolic syndrome. Methods: Fifty-nine subjects with fasting hypertriglyceridemia (≥1.7 mmol/L and <6.9 mmol/L) and two or more of the Adult Treatment Panel III criteria of the metabolic syndrome were randomized to fenofibrate (160 mg/d) or placebo in a double-blind controlled clinical trial. A standardized fat load (50 g/m 2 ) was given after a 12 h fast. Blood specimens were obtained at fasting and 3.5 h and 8 h after the test meal. Results: After the test meal, postprandial (area under the curve) NEFA increased (mean ± SEM) by 11.2 ± 5.1% in the placebo group; in contrast NEFA decreased by 18.6 ± 3.8% in the fenofibrate group ( P =0.0001). No differences in fasting NEFA were observed between groups ( P =0.16). Fenofibrate reduced postprandial triglycerides (−45.4%, P <0.0001) and significantly decreased postprandial large (−40.8%, P <0.0001) and medium (−49.5%, p<0.0001) very low-density lipoprotein (VLDL) particles, as well as small LDL (−40.3%, P <0.0001) and total LDL particles (−19.0%, P <0.005). Reduction in NEFA (AUC) correlated with reductions in postprandial triglycerides (r=0.73, P <0.0001), non-HDL-C (r=0.67, P <0.0001) and with increases in HDL-C (r=0.38, P <0.01). The reduction in NEFA was more strongly correlated with decreased large VLDL (r=0.72, P <0.0001) than medium VLDL (r=0.34, P <0.02) or small VLDL particles (r=0.22, P <0.13). Postprandial reductions in NEFA were also correlated with lowering of small LDL (r=0.53, P <0.0001) and total LDL particles (r=0.60, P <0.0001). Conclusions: Treatment with fenofibrate significantly decreases postprandial NEFA and the reductions in NEFA are highly correlated with reductions in triglycerides, non-HDL-C and an increase in HDL-C. Postprandial NEFA are an important predictor of postprandial lipoprotein changes in subjects with hypertriglyceridemia.

Sign in / Sign up

Export Citation Format

Share Document